APOA1 and metabolic dysfunction-associated steatotic liver disease: Interestingly, administration of APOA1Milano, a gain-of-function mutant of APOA1, by adenovirus-mediated gene transfer in Apoa1−/− mice reduced hepatic lipid deposition and improved hepatic architecture, reinforcing the notion that reduced plasma APOA1 levels are important regulators of NAFLD [48].